Latest Information Update: 10 Jul 1998
At a glance
- Originator Chugai Pharmaceutical
- Developer Asahi Glass; Chugai Pharmaceutical
- Class Calcium regulators; Osteoporosis therapies
- Mechanism of Action Calcitonin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 10 Jul 1998 Discontinued-Preclinical for Postmenopausal osteoporosis in Japan (Unknown route)
- 25 Sep 1996 New profile
- 25 Sep 1996 Preclinical development for Postmenopausal osteoporosis in Japan (Unknown route)